The Lancet Haematology
Fecha de publicación: 1 november 2018
Autores: Prof Takashi Watanabe, MD., Kensei Tobinai, MD., Masashi Wakabayashi, MSc., Yasuo Morishima, MD., Hirofumi Kobayashi, MD., Tomohiro Kinoshita, MD
Background: Standard treatment for untreated advanced-stage follicular lymphoma is rituximab plus chemotherapy. The incidence of histological transformation of follicular lymphoma has been reported only in heterogeneously treated populations and rarely with long-term follow-up.